Sophiris Bio Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sophiris Bio Inc.
Public Company Edition: Also, Roivant and two other biopharma firms close SPAC mergers and begin trading on the Nasdaq, Spero negotiated a royalty financing worth up to $125m and Phathom secured a $200m term loan.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.
- Large Molecule
- Other Names / Subsidiaries
- Protox Therapeutics, Inc.
- Sophiris Bio, Inc.
- Sophiris Bio Corp., Sophiris Bio Holding Corp.